Iron: Cardiac Function in Iron Deficiency and Heart Failure Research

This article is for informational purposes only and does not constitute medical advice. Always consult your cardiologist, internist, or healthcare provider before starting any supplement, especially if you have a diagnosed heart condition or take cardiovascular medications. Dietary supplements are not evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.

SterlingMedicalCenter.org Research Team | July 2026

Iron: Cardiac Function in Iron Deficiency and Heart Failure Research

Paradoxical Cardiac Iron Physiology: Deficiency Versus Excess

Iron occupies a paradoxical position in cardiac health: iron deficiency impairs myocardial function and worsens heart failure prognosis through reduced hemoglobin-mediated oxygen delivery and iron-dependent enzyme suppression, yet iron excess (hemochromatosis, transfusion-related iron overload) causes oxidative cardiomyopathy and arrhythmias through Fenton chemistry–catalyzed free radical generation. Emerging evidence demonstrates that iron deficiency, even without anemia, is present in 20-40% of heart failure patients (particularly HFpEF) and correlates independently with worse symptom severity, reduced exercise tolerance, and worse prognosis. Conversely, iron supplementation in iron-replete individuals (or unopposed iron overload) poses cardiovascular and oxidative stress risks. Current evidence is Strong for iron deficiency as a heart failure prognostic marker; Moderate for iron repletion improving HF outcomes in deficient populations; Strong for iron toxicity in overload states.

Biochemistry: Myocardial Oxygen Delivery and Mitochondrial Energy Production

Iron serves two critical cardiac functions: (1) as the central atom in hemoglobin (oxygen-carrying capacity) and myoglobin (intramyocardial oxygen storage), and (2) as a cofactor for iron-sulfur cluster enzymes involved in mitochondrial electron transport chain (cytochrome c oxidase, succinate dehydrogenase, aconitase) and tricarboxylic acid cycle enzymes. In iron deficiency, hemoglobin drops (reducing systemic oxygen delivery), and mitochondrial iron-dependent enzymes are depleted, impairing ATP synthesis. The heart, being an obligate aerobic organ with minimal anaerobic capacity, is exquisitely sensitive to iron deficiency; even mild iron depletion (low ferritin, normal hemoglobin) can impair myocardial energetics and contractility. Conversely, iron excess generates hydroxyl radicals via the Fenton reaction (Fe2+ + H2O2 → Fe3+ + OH• + OH-), causing lipid peroxidation, myocardial fibrosis, and cardiomyopathy.

Cardiovascular Research: Iron Deficiency in Heart Failure

Iron Deficiency as Independent HF Prognostic Marker: Multiple observational studies demonstrate that iron deficiency (defined as ferritin <100 ng/mL AND transferrin saturation <20%, or serum iron <60 mcg/dL) is independently associated with worse functional capacity, higher NYHA class, reduced 6-minute walk distance, and worse event-free survival in heart failure cohorts. Notably, iron deficiency HF patients often have normal hemoglobin and are missed by clinical assessment focusing solely on anemia. The prevalence of iron deficiency in heart failure is 20-40% depending on cohort selection.

Iron Repletion in HFrEF (Reduced Ejection Fraction): The CONFIRM-HF trial and smaller RCTs with intravenous iron sucrose (1-3 g cumulative IV over 1-4 weeks) in iron-deficient HFrEF patients demonstrated improvements in symptom severity, exercise capacity (6-minute walk distance improvement of 30-50 meters), and quality of life measures. LVEF improvements were modest (2-5% in some studies). However, trials remain relatively small (n=30-200 per study), and no large-scale mortality reduction trial with IV iron in HF has been completed. Furthermore, most evidence derives from IV iron administration rather than oral supplementation, which has much poorer absorption and efficacy in HF populations.

HFpEF (Preserved Ejection Fraction) and Iron Deficiency: A growing body of observational data suggests that iron deficiency is particularly prevalent and symptomatic in HFpEF populations. Small prospective studies of IV iron repletion in iron-deficient HFpEF patients suggest improvements in dyspnea, functional capacity, and quality of life, though hard outcome data are lacking.

Iron Overload and Cardiomyopathy: In contrast to deficiency, iron overload through hemochromatosis (hereditary or transfusion-related) causes dilated cardiomyopathy, conduction abnormalities, and heart failure through myocardial fibrosis and oxidative damage. This risk is relevant to patients receiving chronic blood transfusions (thalassemia, sickle cell disease) or with hereditary hemochromatosis, not typical cardiac patients on supplementation.

Iron Supplementation: Critical Distinctions Between Oral and Intravenous

Intravenous Iron (Proven Efficacy in HF): Intravenous iron sucrose, iron carboxymaltose, and iron dextran formulations bypass gastrointestinal absorption limitations and achieve rapid iron repletion. Most heart failure trials supporting iron repletion employed IV iron administered in hospital or outpatient infusion centers. IV iron is appropriate for HF patients with documented iron deficiency, particularly those with impaired GI absorption (common in advanced HF due to gut congestion and edema). Dosing: iron sucrose 200 mg IV weekly until iron stores replete (typically 1-3 g total over 4-12 weeks), monitored by repeat serum iron studies.

Oral Iron Supplementation (Limited Efficacy in HF): Oral iron supplementation has poor bioavailability in heart failure due to gut mucosal edema, impaired absorption, and GI side effects. Ferrous sulfate, ferrous gluconate, and ferrous fumarate (standard forms) have absorption rates of only 10-30% in healthy individuals and lower in HF populations. Ferric iron supplements (ferric citrate, ferric sulfate) have marginally better absorption but remain suboptimal for HF patients needing iron repletion. Oral iron may help prevent worsening deficiency in HF patients with chronic GI blood loss but is unlikely to substantially replete depleted iron stores.

Clinical Recommendation: For symptomatic HF patients with documented iron deficiency, IV iron repletion by cardiologist/HF specialist is preferred over oral supplementation. However, oral iron supplementation at 325 mg ferrous sulfate daily (providing ~65 mg elemental iron) may serve a maintenance role in patients with mild iron deficiency or after IV repletion to prevent recurrent deficiency.

Iron Assessment and Monitoring in Cardiac Populations

Iron status is evaluated through a panel: serum iron (normal 60-170 mcg/dL), ferritin (normal 30-400 ng/mL, but varies by sex and age), and transferrin saturation (normal 20-50%). In heart failure, iron deficiency is typically defined as ferritin <100 ng/mL (or <30 ng/mL in some guidelines) AND transferrin saturation <20%, or as absolute iron deficiency with frank low serum iron. Hemoglobin and hematocrit are often normal despite iron deficiency. Testing iron status is recommended in all newly diagnosed heart failure patients, particularly those with reduced exercise capacity or persistent dyspnea despite medical optimization.

Drug Interactions and Cardiac Medication Considerations

Interactions with Oral Iron Supplementation:

ACE Inhibitors and Arbs: No direct pharmacokinetic interactions; however, these medications may modestly increase hemoglobin through improved renal perfusion and erythropoietin signaling. Concurrent iron supplementation is safe and potentially synergistic for HF patients with both iron and hemoglobin insufficiency.

Beta-Blockers: No significant iron interaction; safe concurrent use.

Diuretics: Loop diuretics and thiazides can increase urinary iron and other mineral losses; HF patients on chronic diuretics may have mild secondary iron deficiency. Iron supplementation may partially compensate, though the primary iron loss in HF is often occult GI blood loss rather than renal wasting.

Proton Pump Inhibitors (PPIs) and H2-Blockers: These medications reduce gastric acid and significantly impair oral iron absorption. Heart failure patients on PPIs have reduced oral iron bioavailability; IV iron is preferable, or oral iron should be taken apart from PPI dosing (several hours separation) if oral route is chosen.

Antibiotic Interactions: Certain antibiotics (quinolones, tetracyclines) form insoluble complexes with iron and should be separated in timing from iron supplementation by at least 2 hours.

IV Iron Considerations: IV iron carries risk of anaphylactic reactions (rare with modern formulations like iron sucrose <0.1% anaphylaxis risk) and transient hypotension; cardiac patients, particularly those with marginal hemodynamic compensation, should receive IV iron in monitored settings with appropriate resuscitation equipment available.

Who Should Be Tested and Supplemented / Who Should Avoid Iron Supplementation

Should Test Iron Status and Consider Supplementation: All heart failure patients at baseline and periodically during follow-up; HF patients with reduced exercise capacity or persistent dyspnea despite guideline-directed medical therapy; those with any evidence of anemia or GI blood loss; cardiac patients with chronic kidney disease (CKD often accompanies HF and causes secondary iron deficiency); post-cardiac surgery patients experiencing delayed functional recovery.

Should Receive IV Iron (Preferred Route in HF): Symptomatic HF patients with documented iron deficiency; those with impaired GI absorption (gut edema, chronic diarrhea); patients intolerant to oral iron (GI side effects, nausea); those with ongoing GI blood loss.

Oral Iron as Secondary Option: Iron-deficient HF patients who refuse IV administration; those with mild iron deficiency pursuing maintenance supplementation post-IV repletion; non-HF cardiac patients with iron deficiency anemia (assuming adequate GI absorption).

Should Avoid Iron Supplementation (Risk of Overload): Patients with hereditary hemochromatosis or documented iron overload; those with ongoing transfusion requirements (thalassemia, sickle cell disease); patients with ferritin levels consistently >300 ng/mL without documented iron deficiency; those with active hemolysis (increased iron recycling).

Caution with Routine Iron Supplementation: Healthy individuals without documented iron deficiency — the heart is sensitive to iron overload, and routine supplementation in replete individuals poses oxidative risk. Males (who lack menstrual iron loss) particularly should not routinely supplement without deficiency evidence.

Clinical Perspective: Iron as Emerging HF Therapeutic Target

Iron deficiency has emerged as an overlooked yet modifiable HF prognostic factor, particularly in HFpEF populations where few therapeutic options exist. The evidence supporting IV iron repletion in iron-deficient HF patients is accumulating, though outcome trials remain relatively small and limited to symptom improvement rather than mortality reduction. The critical clinical distinction is that oral iron supplementation has poor efficacy in HF due to absorption limitations, whereas IV iron repletion is increasingly recognized as standard of care for iron-deficient HF patients. All cardiac patients, particularly those with heart failure, should have iron status assessed; deficiency should be corrected, preferably through IV administration in HF contexts. Routine iron supplementation in cardiac patients without documented deficiency is not recommended and may pose oxidative risk. For comprehensive information on HF biomarker-driven management and micronutrient physiology in heart disease, see SterlingMedicalCenter.org resources.

This ingredient profile is provided for educational purposes only. It does not constitute medical advice, a treatment recommendation, or a substitute for evaluation by a qualified cardiologist, internist, or healthcare provider. Cardiac patients should discuss all supplement use with their cardiology care team before starting, stopping, or changing any supplement. Individual responses to supplements vary. SterlingMedicalCenter.org is an independent editorial publication and is not affiliated with any hospital, clinic, cardiology practice, or medical provider.